Among the key genes identified, MYC, NOTCH1, TOP2A, CD44, PTPRC, SSRP1, CDK4, DKC1, HNRNPU, and PDGFRA have shown significant correlations with GBM prognosis and may serve as potential targets for therapeutic interventions. The gene discussed is HNRNPU; the disease is glioblastoma.